Related Experiment Video
Updated: May 21, 2026
07:32
Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining
Published on: May 23, 2025
Neurodegeneration with brain iron accumulation
Petr Dusek1, Susanne A Schneider
1Department of Neurology, Center of Clinical Neuroscience, 1st Faculty of Medicine, General University Hospital in Prague, Charles University in Prague, Prague, Czech Republic. pdusek@gmail.com
Current Opinion in Neurology
|June 14, 2012
Summary
Recent discoveries in neurodegeneration with brain iron accumulation (NBIA) include new gene mutations and insights into chelating drug treatments. While some treatments show promise for individual patients, deep brain stimulation is advancing for symptomatic relief.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Neurodegeneration with brain iron accumulation (NBIA) encompasses a group of rare genetic disorders.
- Recent advancements have identified novel genes responsible for NBIA, leading to a revised classification scheme.
- Emerging research explores the efficacy of modern chelating drugs for NBIA treatment.
Purpose of the Study:
- To review the clinical presentations of newly identified NBIA syndromes.
- To summarize diagnostic clues for differentiating NBIA subtypes.
- To discuss current and emerging treatment strategies for NBIA.
Main Methods:
- Literature review of recent studies on NBIA genetics and treatment.
- Analysis of clinical phenotypes associated with novel NBIA gene mutations.
- Evaluation of outcomes from chelating drug trials and deep brain stimulation studies.
Main Results:
- Mutations in the c19orf12 gene identified in a novel NBIA subtype with a PKAN-like phenotype.
- Fatty-acid 2-hydroxylase gene mutations linked to phenotypes combining leukodystrophy and NBIA.
- Chelating treatments showed limited efficacy in a pilot PKAN study but offered benefits in individual NBIA cases.
Conclusions:
- New NBIA syndromes have distinct clinical features and diagnostic considerations.
- Chelating treatment for NBIA remains experimental, with variable patient responses.
- Deep brain stimulation shows promise for managing generalized dystonia in NBIA patients.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...